CD276 Protein (CD276) (AA 29-245)

Catalog No. ABIN6253388

Recombinant CD276 protein expressed in HEK-293 Cells.

Quick Overview for CD276 Protein (CD276) (AA 29-245) (ABIN6253388)

Target: CD276

Protein Type: Recombinant

Origin: Human

Source: HEK-293 Cells

Purity: >95 % (SDS-PAGE)

Product Details

Protein Characteristics: AA 29-245

Purpose: CD276 [B7-H3] (human) (rec.)

Specificity: The extracellular domain of human CD276 [B7-H3] (aa 29-245) is untagged.

Characteristics: Protein. The extracellular domain of human CD276 [B7-H3] (aa 29-245) is untagged. Source: HEK 293 cells. Endotoxin content: <0.01EU/μg protein (LAL test, Lonza). Lyophilized from 0.2μm-filtered solution in PBS. Purity: >95 % (SDS-PAGE). CD276 (B7-H3) is a member of the B7/CD28 superfamily of costimulatory molecules serving as an accessory modulator of T cell response. B7 family molecules, which are expressed on antigen-presenting cells and display extracellular regions containing immunoglobulin (Ig) variable (V)- and constant (C)-like domains, are known to modulate T cell receptor (TCR)-mediated T cell activation by providing co-signals that are either stimulatory or inhibitory. B7-H3 provides a stimulatory signal to T cells. However, recent studies suggest a negative regulatory role for B7-H3 in T cell responses. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3 is a negative regulator that preferentially affects T(H)1 responses. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. Recently, B7-H3 expression has also been found in a variety of different human cancers, including prostate cancer, clear cell renal cell carcinoma (ccRCC), non-small-cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, ovarian cancer, colorectal cancer (CRC) and urothelial cell carcinoma. B7-H3 was expressed in some human cancers and correlated with poor outcome of cancer patients.

Endotoxin Level: <0.01EU/μg protein (LAL test, Lonza).

Biological Activity Comment: Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: Lot specific

Buffer: Lyophilized from 0.2μm-filtered solution in PBS.

Handling Advice: Avoid freeze/thaw cycles. PBS containing at least 0.1 % BSA should be used for further dilutions.

Storage: 4 °C,-20 °C

Storage Comment:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.

Target Details

Target: CD276

Alternative Name: CD276 [B7-H3]

Background:

Alternate Names/Synonyms: B7-H3

Product Description: CD276 (B7-H3) is a member of the B7/CD28 superfamily of costimulatory molecules serving as an accessory modulator of T cell response. B7 family molecules, which are expressed on antigen-presenting cells and display extracellular regions containing immunoglobulin (Ig) variable (V)- and constant (C)-like domains, are known to modulate T cell receptor (TCR)-mediated T cell activation by providing co-signals that are either stimulatory or inhibitory. B7-H3 provides a stimulatory signal to T cells. However, recent studies suggest a negative regulatory role for B7-H3 in T cell responses. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3 is a negative regulator that preferentially affects T(H)1 responses. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. Recently, B7-H3 expression has also been found in a variety of different human cancers, including prostate cancer, clear cell renal cell carcinoma (ccRCC), non-small-cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, ovarian cancer, colorectal cancer (CRC) and urothelial cell carcinoma. B7-H3 was expressed in some human cancers and correlated with poor outcome of cancer patients.

Molecular Weight: ~35kDa (SDS-PAGE)

NCBI Accession: NP_079516

Pathways: Cancer Immune Checkpoints